arrow
K

Kathryn A. Gold

 ohio state university
H指数:34
被引数:6,908

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

B cell subsets are associated with durable responses in distinct cancer types after immune checkpoint inhibition

B细胞亚群与免疫检查点抑制后不同癌症类型的持久性反应相关

2026-10-280
PRE
Small Cell Lung Cancer, Version 2.2026 Featured Updates to the NCCN Guidelines

小细胞肺癌,2026年第2版NCCN指南特色更新

2026-01-010
PRE
Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort

在前瞻性口腔癌前队列中,空间PD-L1,免疫细胞微环境和基因组拷贝数改变模式以及浸润性疾病转变的驱动因素

CANCER
IF5.1
2023-01-038
OAAI
Small Cell Lung Cancer, Version 2.2022

小细胞肺癌2.2022版

2021-12-01233
OA
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer

Patritumab Deruxtecan (HER3-DXd) 在EGFR抑制剂耐药,EGFR突变的非小细胞肺癌中的疗效和安全性

2021-09-21175
OAAI
Avelumab and cetuximab as a therapeutic combination: An overview of scientific rationale and current clinical trials in cancer

Avelumab和西妥昔单抗作为治疗组合: 癌症的科学原理和当前临床试验概述

2021-06-0134
OAAI
Planning for post-pandemic cancer care delivery: Recovery or opportunity for redesign?

大流行后癌症护理提供的规划: 恢复还是重新设计的机会?

2020-09-3016
OAAI
Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma
2019-03-0118
OAAI